NR2F2 and prostate carcinoma: The negative transcription regulation was further validated by prostate cancer patient specimen analysis, in which there was a significant and negative correlation between MPC1 and COUP-TFII expression, consistent with the notion that COUP-TFII may serve as an upstream regulator to control MPC1 expression in patients (Figure 2C).